Vaxcyte Inc logo

PCVX - Vaxcyte Inc News Story

$22.97 0.0  0.0%

Last Trade - 14/06/21

Sector
Healthcare
Size
Mid Cap
Market Cap £836.3m
Enterprise Value £608.7m
Revenue £n/a
Position in Universe 2792nd / 6917

Vaxcyte to Present at BofA Securities 2021 Health Care Conference

Thu 6th May, 2021 9:05pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210506:nGNX2DVcxh&default-theme=true


FOSTER CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq:
PCVX), a next-generation vaccine company seeking to improve global health by
developing superior and novel vaccines designed to prevent or treat some of
the most common and deadly infectious diseases worldwide, today announced that
Company management will present at the BofA Securities 2021 Health Care
Conference on Thursday, May 13, 2021 at 3:30pm ET.

A live webcast of the presentation can be accessed through the Investors &
Media section of the Company’s website at http://investors.vaxcyte.com. A
replay of the webcast will be available for approximately 30 days following
the conference.

About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health
by developing superior and novel vaccines designed to prevent or treat some of
the most common and deadly infectious diseases worldwide. The Company’s
cell-free protein synthesis platform, comprising the XpressCF(TM) platform,
exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s
proprietary know-how, enables the design and production of protein carriers
and antigens, the critical building blocks of vaccines, in ways that the
Company believes conventional vaccine technologies currently cannot.
Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent
broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the
prevention of invasive pneumococcal disease (IPD). Vaxcyte’s pipeline also
includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30
strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A
Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow
or stop the progression of periodontal disease by targeting the keystone
pathogen responsible for this chronic, oral inflammatory disease. For more
information, visit www.vaxcyte.com.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor
Relations 
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/40247556-3f53-4f9a-999e-7929a3eaee0a)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.